Mustang Bio (MBIO) Prices 10.79M Share Common Offering at $3.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
Mustang Bio Announces Pricing of Public Offering of Common Stock
June 11, 2020 9:01 AM EDTWORCESTER, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced the pricing of its previously announced underwritten public offering. Mustang is offering 10,769,231 shares of its common stock, par value $0.0001 per share, at a price to the public of $3.25 per share. In connection with the offering, Mustang has also granted the underwriter a 30-day option to purchase up to an additional 1,615,384... More
